

| MONDAY 6 SEPTEMBER |   |
|--------------------|---|
| 11.00am            | Registration and Exhibition and Poster Area opens   |
| 1.00pm - 3.00pm    | <b>Opening Ceremony &amp; Plenary: Innovations and Challenging Orthodoxy</b>  |
|                    | Grand 1 - 4<br>Chairs: Geoff McCaughan & Helen Tyrrell  |
| 1.00pm - 1.05pm    | Welcome to the Land Speaker, Margaret Gardiner  |
| 1.05pm - 1.10pm    | Welcome by Levinia Crooks, CEO, Australasian Society for HIV Medicine   |
| 1.10pm - 1.15pm    | Introduction by Geoff McCaughan, Representative of the 2010 Viral Hepatitis Conference Partners   |
| 1.15pm - 1.20pm    | Announcement of the Innovation Award Recipients, Greg Dore, President, Australasian Society for HIV Medicine  |
| 1.20pm - 1.45pm    | <b>Maria Prins, Senior Epidemiologist, Head Department of Research, Cluster Infectious Diseases, Health Service of Amsterdam, The Netherlands</b><br><br>Changing times in hepatitis C epidemiology   |
| 1.45pm - 2.10pm    | <b>Edward Gane, Hepatologist, New Zealand Liver Transplant Unit, New Zealand</b><br><br>New directions in hepatitis C therapy   |
| 2.10pm - 2.35pm    | <b>Helen Watchirs, ACT Human Rights and Discrimination Commissioner, ACT, Australia</b><br><br>Human rights and discrimination issues related to blood borne viruses  |
| 2.35pm - 3.00pm    | <b>Robert Gish, Gastroenterologist, Medical Director, Liver Disease Management and Transplant Program, California Pacific Medical Center, California, United States of America</b><br><br>New hepatitis B treatments: Long-term therapy: balancing the risk and benefits as we pursue sustained viral clearance |
| 3.00pm - 3.30pm    | Afternoon Tea in Exhibition and Poster Area, Grand Foyer  |

|                 |  |                 |  |
|-----------------|--|-----------------|--|
| 3.30pm - 5.00pm | <b>The Shifting Focus of Hepatitis B Supported by Australian Government Department of Health &amp; Ageing</b><br>Grand 1 - 4<br>Chairs: Robert Gish & Nghi Phung   | 3.30pm - 5.00pm | <b>HCC: The Problem is Now</b><br>Grand 5 & 6<br>Chairs: Monica Robotin & Mariam Levy  |
| 3.30pm - 3.50pm | <b>Benjamin Cowie, Epidemiologist, Victorian Infectious Diseases Service, Royal Melbourne Hospital, VIC, Australia</b><br><br>Something old, something new: The epidemiology of hepatitis B in Australia | 3.30pm - 3.50pm | <b>Nick Shackel, Senior Lecturer, Medicine, Central Clinical School, Centenary Institute of Cancer Medicine &amp; Cell Biology, University of Sydney, NSW, Australia</b><br><br>Genomics is necessary to maximise treatment outcomes |
| 3.50pm - 4.10pm | <b>Edward Gane, Hepatologist, New Zealand Liver Transplant Unit, New Zealand</b><br><br>Screening hepatitis B in the community: Effect on therapy uptake   | 3.50pm - 4.10pm | <b>Rosie Thien, Lecturer, Viral Hepatitis Clinical Research Program, National Centre in HIV Epidemiology and Clinical Research, NSW, Australia</b><br><br>Epidemiological overview of hepatocellular carcinoma                       |
| 4.10pm - 4.30pm | <b>Kumar Visvanathan, Infectious Disease Physician, Monash Medical Centre, VIC, Australia</b><br><br>Pathogenesis of hepatitis B infection   | 4.10pm - 4.30pm | <b>Paul Gow, Deputy Director, Gastroenterology Unit, Austin Hospital, VIC, Australia</b><br><br>Current treatment paradigms  |
| 4.30pm - 5.00pm | Discussion   | 4.30pm - 5.00pm | Discussion   |
| 5.00pm - 6.30pm | Welcome Reception & Poster Viewing Evening, Grand Foyer<br>Supported by Roche Products   |                 |  |

| TUESDAY 7 SEPTEMBER |   |
|---------------------|---|
| 7.30am              | Registration  |
| 7.30am - 9.00am     | Gilead Satellite Symposium, CHB treatment, endpoints and stopping rules. New agents, better outcomes...<br>Presented by Prof Robert Gish<br>Grand 5 & 6   |
| 9.00am - 10.30am    | Maximising Our Current Knowledge<br>Grand 1 - 4<br>Chairs: Joe Torresi & Margaret Hellard   |
| 9.00am - 9.30am     | <b>Jacob George, Director, Storr Liver Unit, Westmead Millennium Institute of Medical Research, NSW, Australia</b><br>Host genetics and treatment responses in chronic hepatitis C infection  |
| 9.30am - 10.00am    | <b>Carla Treloar, Head, Hepatitis C Program, Deputy Director, National Centre in HIV Social Research, NSW, Australia</b><br>Tackling the fundamentals: Social inclusion and hepatitis C   |
| 10.00am - 10.30am   | <b>Scott L. Friedman, President, American Association for the Study of Liver Diseases, Fishberg and Professor of Medicine, Chief, Division of Liver Diseases, Mount Sinai School of Medicine, New York, United States of America</b><br>Current approaches to anti-fibrotic therapies |
| 10.30am - 11.00am   | Morning Tea in Exhibition and Poster Area, Grand Foyer  |

|                   | Community & Social Research:<br>Understanding Community   |                   | Clinical Medicine: Prediction of Hepatitis C<br>Treatment Response  |                   | Epidemiology, Public Health &<br>Prevention: Models, Mortality and<br>Money - the "Big Picture" of Hepatitis C<br>and Hepatitis B                           |                   | Basic Science: Hepatitis Pathogenesis<br>and Virology  |
|-------------------|---|-------------------|---|-------------------|---|-------------------|--|
| 11.00am - 12.30pm | Grand 1 & 2<br><br>Chairs: Annie Madden &   | 11.00am - 12.30pm | Grand 3 & 4<br><br>Chairs: Jacob George & Simone Strasser   | 11.00am - 12.30pm | Grand 6<br><br>Chairs: Mark Stoove & Emma McBryde   | 11.00am - 12.30pm | Grand 5<br><br>Chairs: David Anderson & Silvana Gaudieri   |
| 11.00am - 11.15am | McNeill H - Hep C: Take control - A chronic disease self management intervention for people with hepatitis C  | 11.00am - 11.15am | Grebely J - Potential role for IL28b genotype in treatment decision-making in recent hepatitis C virus infection  | 11.00am - 11.15am | Wilson D - Evaluating the cost-effectiveness of needle and syringe programs in Australia for preventing hepatitis C infection among people who inject drugs | 11.00am - 11.15am | Prakoso E - Ductular reaction in hepatitis C recurrence post liver transplantation                                     |
| 11.15am - 11.30am | Crawford S - Ensuring research meets community expectation – The development of a community ratification process of research involving people who use drugs in NSW. | 11.15am - 11.30am | Thompson A - IL28b polymorphism determines treatment response of patients with hepatitis C genotypes 2 or 3 who do not achieve a rapid virologic response   | 11.15am - 11.30am | Lauzon C - Change for the better: HIV and hepatitis C seroprevalence among attendees of New Zealand needle exchanges 2004-2009                              | 11.15am - 11.30am | Walsh R - Novel ignar intrabody targeting the hepatitis B virus precore/core antigen                                   |
| 11.30am - 11.45pm | Cairnduff S - Engaging young Aboriginal people in hepatitis C health promotion  | 11.30am - 11.45am | Roberts S - Predicting SVR by combining early measurements of viral load with baseline characteristics including fibrosis score: Enhanced potential to individualise HCV treatment decisions.                   | 11.30am - 11.45am | Thein R - Epidemiological and economic impact of potential increased hepatitis C treatment uptake in Australia  | 11.30am - 11.45am | Torresi J - Differential modulation of stat/socs signaling in HBV/HCV-coinfection                                      |
| 11.45am - 12.00pm | O'Callaghan S - The wellbeing weekend: A holistic approach to living well with hepatitis C  | 11.45am - 12.00pm | Baleriola C - Impact of low level HCV viremia at week 24 on HCV treatment response in genotype 1 patients   | 11.45am - 12.00pm | Matser A - The effect of HCV treatment and HIV coinfection on the future disease burden of hepatitis C among injecting drug users in Amsterdam              | 11.45am - 12.00am | Ratnam D - Toll like receptor agonist induced IFN - Responses by natural killer cells in chronic hepatitis B infection |
| 12.00pm - 12.15pm | Treloar C - Sydney Egyptian communitys understanding of HCV, their knowledge of virus transmission, attitudes towards HCVand treatment.                             | 12.00pm - 12.15pm | Sievert B - Significant hemoglobin (HB) decline during pegylated interferon and ribavirin therapy in HCV genotype 1 is associated with sustained virological response (SVR): An analysis from the chariot study | 12.00pm - 12.15pm | Gidding H - Trends in all cause and liver-related hospital admissions in people notified with hepatitis B and C in New South Wales, Australia               | 12.00pm - 12.15pm | Crane M - LPS: Immune activation and liver disease in HIV-HBV co-infection   |
| 12.15pm - 12.30pm | Wang J - Knowledge & prevention: A hepatitis B survey in the Chinese community  | 12.15pm - 12.30pm | Dore G - Low virological response and high relapse rates in hepatitis C genotype 1 patient's with advanced fibrosis despite adequate therapeutic dosing   | 12.15pm - 12.30pm | Walter S - Causes of death after diagnosis with hepatitis B or C: 1992-2006   | 12.15pm - 12.30pm | Littlejohn M - Evolution of HBV during HBV-active HAART  |

|                  |  |                 |  |                 |  |                 |  |
|------------------|--|-----------------|--|-----------------|--|-----------------|--|
| 12.30pm - 1.30pm | Lunch in Exhibition and Poster Area, Grand Foyer   |                 |  |                 |  |                 |  |
| 1.30pm - 3.00pm  | <b>Management and Treatment of Injecting Drug Users</b>  | 1.30pm - 3.00pm | <b>Moving forward with Hepatitis B Policy and Practice</b>   | 1.30pm - 3.00pm | <b>Current Challenges in HCV Therapies</b>   | 1.30pm - 3.00pm | <b>Hepatitis C, Immunity and Pathogenesis</b>  |
| 1.30pm - 3.00pm  | Grand 1 & 2<br>Chairs: Maria Prins & Jacqui Richmond   | 1.30pm - 3.00pm | Grand 3 & 4<br>Chairs: Benjamin Cowie & Jack Wallace   | 1.30pm - 3.00pm | Grand 6<br>Chairs: Amany Zekry & Stuart Roberts  | 1.30pm - 3.00pm | Grand 5<br>Chairs: Peter Angus & Andrew Lloyd  |
| 1.30pm - 1.50pm  | <b>Margaret Hellard, Head, Centre for Population Health, Burnet Institute, VIC, Australia</b><br><br>Myths and reality: Managing IDUs with hepatitis C                                   | 1.30pm - 1.50pm | <b>Jack Wallace, Research Fellow, Australian Research Centre in Sex, Health and Society, Latrobe University, VIC, Australia and Benjamin Cowie, Epidemiologist, Victorian Infectious Diseases Service, Royal Melbourne Hospital, VIC, Australia</b><br><br>Setting the scene: A social and community perspective and<br>Setting the scene: An epidemiology and public health perspective | 1.30pm - 1.50pm | <b>William Sievert, Director, Gastrointestinal and Liver Unit, Monash Medical Centre and Dandenong Hospital, VIC, Australia</b><br><br>Is retreatment worthwhile | 1.30pm - 1.50pm | <b>David Bowen, Senior Lecturer, Medicine, Central Clinical School, Centenary Institute, University of Sydney, NSW, Australia</b><br><br>Immunological determinants of HCV control and clearance   |
| 1.50pm - 2.10pm  | <b>Annie Madden, Executive Officer, Australian Injecting &amp; Illicit Drug Users League</b><br><br>Hepatitis C treatment and injecting drug users: On a tightrope without a safety net? | 1.50pm - 2.10pm | <b>Lisa Ryan, Manager, Harm Minimisation, NSW Department of Health, NSW, Australia</b><br><br>Implementation of the first national hepatitis B strategy: A NSW perspective   | 1.50pm - 2.10pm | <b>Simone Strasser, Royal Prince Alfred Hospital, A W Morrow Gastroenterology and Liver Centre, NSW, Australia</b><br><br>Treating advanced disease              | 1.50pm - 2.10pm | <b>Scott L. Friedman, President, American Assn. for the Study of Liver Diseases, Fishberg and Professor of Medicine, Chief, Division of Liver Diseases, Mount Sinai School of Medicine, New York, United States of America</b><br><br>Basic mechanisms of fibrosis |

|                 |  |                 |   |                 |   |                 |   |
|-----------------|--|-----------------|---|-----------------|---|-----------------|---|
| 2.10pm - 2.30pm | <p><b>Greg Dore, Professor and Head, Viral Hepatitis Clinical Research Program, National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, NSW, Australia</b></p> <p>Partnerships to enhance hepatitis C treatment uptake and outcomes among injecting drug users</p> | 2.10pm - 2.30pm | <p><b>Lisa Maher, Professor and Head, Viral Hepatitis Epidemiology and Prevention Program, National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, NSW, Australia</b></p> <p>Hepatitis B and people who inject drugs: challenges, innovations and opportunities</p> | 2.10pm - 2.30pm | <p><b>Paul Desmond, Director, Department of Gastroenterology, St. Vincent's Hospital, VIC, Australia</b></p> <p>Personalising therapy</p> | 2.10pm - 2.30pm | <p><b>Eric Gowans, Executive Director, Women's and Children's Health Research Institute, SA, Australia</b></p> <p>Vaccine prospects for HCV</p> |
| 2.30pm - 3.00pm | Discussion   | 2.30pm - 2.50pm | <p><b>Steven Tipper, Manager, Scientific Development, Research Strategy &amp; Scientific Development Unit, The Cancer Council NSW, NSW, Australia</b></p> <p>The B positive project: challenges in CALD community engagement and GP education</p>   | 2.30pm - 3.00pm | Discussion  | 2.30pm - 3.00pm | Discussion  |
| 2.50pm - 3.00pm |  | 2.50pm - 3.00pm | Discussion  |                 |   |                 |   |
| 3.00pm - 3.30pm | <p>Afternoon Tea in Exhibition and Poster Area, Grand Foyer<br/>         Multi Media Presentation, Is treatment right for you?, Louise Smith, Grand 6</p>  |                 |   |                 |   |                 |   |

| 3.30pm - 5.00pm | Community & Social Research: Cultures, Communities and Hepatitis C Treatment  | 3.30pm - 5.00pm | Epidemiology, Public Health & Prevention: Hepatitis B and Hepatitis C Transmission and Clearance – What's New  | 3.30pm - 5.00pm | Clinical Medicine: Across the Spectrum, Post Populations   | 3.30pm - 5.00pm | Basic Science: Immunology of Hepatitis Viruses   |
|-----------------|---|-----------------|--|-----------------|--|-----------------|--|
|                 | Grand 1 & 2<br>Chairs: Jim Hyde & Max Mopwood   |                 | Grand 3 & 4<br>Chairs: Lisa Maher & Jason Grebely  |                 | Grand 6<br>Chairs: Paul Desmond & Bill Sievert   |                 | Grand 5<br>Chairs: Eric Gowans & Mandvi Bharadwaj  |
| 3.30pm - 3.45pm | Honey C - The changing arrangements for access to hepatitis C treatment and care services across NSW  | 3.30pm - 3.45pm | Winter R - Prevalence and incidence of hepatitis B virus exposure and vaccination in a Melbourne cohort of people who inject drugs   | 3.30pm - 3.45pm | Thompson A - IL28b polymorphism, jaundice during acute HCV infection, and spontaneous clearance in the German anti-d cohort  | 3.30pm - 3.45pm | Johnson D - Novel adjuvants to increase humoral neutralising antibody and cellular immune responses to recombinant mammalian cell derived hepatitis C virus-like-particles |
| 3.45pm - 4.00pm | McNally S - Share care: Do we need a model?   | 3.45pm - 4.00pm | Sacks-Davis R - Elispot testing shows very few people who inject drugs avoid hepatitis C virus exposure  | 3.45pm - 4.00pm | Matthews G - Differences in early virological decline in individuals treated within the Australian trial in acute HCV suggest a potential benefit for the use of ribavirin       | 3.45pm - 4.00pm | Grant E - Novel measures for induction of effective hepatitis C virus-specific T cell immunity   |
| 4.00pm - 4.15pm | Brener L - Evaluation of a hepatitis C community clinic in Christchurch, New Zealand  | 4.00pm - 4.15pm | Lloyd A - HCV incidence and infection outcome in a follow-up study of high-risk IDU prison inmates   | 4.00pm - 4.15pm | Manoharan S - Lamivudine in the last trimester of pregnancy for prevention of HBV transmission: Post-partum hepatic flares and development of genotypic nucleos(t)ide resistance | 4.00pm - 4.15pm | Flynn J - Altered cytokine responses in HCV-infected subjects treated with interferon-alpha  |
| 4.15pm - 4.30pm | Te Au H - Hepatitis C resource centre Otago and the local needle exchange started providing blood testing on site   | 4.15pm - 4.30pm | Grebely J - Hepatitis C virus genotype and female sex are independently associated with spontaneous clearance during acute infection - findings from an international collaboration (INC3) | 4.15pm - 4.30pm | Hajarizadeh B - Comparing the cost-effectiveness of three- versus two-dose vaccination schedule against hepatitis b in adolescents. Experience of a developing country           | 4.15pm - 4.30pm | Wilson R - Genotype-specific suppression of TIR-mediated innate immunity by the hepatitis B E antigen  |
| 4.30pm - 4.45pm | Everingham H - Enhanced treatment for hepatitis C in opioid substitution settings (ethos) - exploring the role of peer support in the delivery of hepatitis C treatment | 4.30pm - 4.45pm | Hellard M - Hepatitis C transmission and clearance in a cohort of injecting drug users – A highly dynamic process  | 4.30pm - 4.45pm | Carville K - Does hepbhelp help? An evaluation of a web-based resource for the care of patients with newly diagnosed chronic hepatitis B in Victoria                             | 4.30pm - 4.45pm | Llyod A - Evaluation of potentially protective immunity in highly exposed, but uninfected prison inmates in the hits study   |
| 4.45pm - 5.00pm | Rance J - The politics of place(ment): Treating hepatitis C within opiate substitution  | 4.45pm - 5.00pm | Pham S - Infection with multiple HCV strains in a prison cohort of seronegative injecting drug users   | 4.45pm - 5.00pm | Shadur B - The changing epidemiology of hepatitis D in Australia: Challenging our clinical response  | 4.45pm - 5.00pm | Bharadwaj M - CTL escape by evasion of T cell recognition in hepatitis c virus infection   |
| 7.00pm          | Conference Dinner, The Carousel, Albert Park  |                 |  |                 |  |                 |  |

| WEDNESDAY 8 SEPTEMBER |  |                   |   |                   |  |                   |   |
|-----------------------|--|-------------------|---|-------------------|--|-------------------|---|
| 7.30am                | Registration   |                   |   |                   |  |                   |   |
| 9.00am - 10.30am      | <b>Community &amp; Social Research: The Cutting Edge of Social Research</b>  | 9.00am - 10.30am  | <b>Epidemiology, Public Health &amp; Prevention: Prevention, Prison &amp; Patient Models of Care</b>  | 9.00am - 10.30am  | <b>Clinical Medicine: Enhancing Hepatitis C Treatment and Care</b>   | 9.00am - 10.30am  | <b>Basic Science: Host Genetics and Cell Biology</b>  |
|                       | Grand 1 & 2<br>Chairs: Meredith Temple-Smith & Sandra Gregson  |                   | Grand 3 & 4<br>Chairs: Sally Bell & Michael Levy  |                   | Grand 6<br>Chairs: Fran Bramwell   |                   | Grand 5<br>Chairs: Joe Toressi & Alex Thompson  |
| 9.00am - 9.15am       | Fry M - Rising to the challenge of self-managing hepatitis C: The mixed impact of disclosure   | 9.00am - 9.15am   | Stoove M - Intraprison injecting risk practices and post-release blood borne virus transmission: Results from a post-prison release cohort study of people who inject drugs | 9.00am - 9.15am   | Salehi Alavi M - Impact of pegylated interferon alfa-2a treatment on depression during recent HCV infection: the Australian Trial in Acute Hepatitis C (ATAHC) | 9.00am - 9.15am   | Thompson A - IL28B polymorphism is associated with intrahepatic ISG expression in patients with chronic HCV infection   |
| 9.15am - 9.30am       | Seear K - The sneaky virus: Constituting hepatitis C through health promotions literature  | 9.15am - 9.30am   | Huber C - Maximising hepatitis C prevention in hard to reach populations utilising the pharmacy sector  | 9.15am - 9.30am   | Blacklaws H - Irritability: An under-appreciated side effect of interferon treatment for chronic hepatitis C?  | 9.15am - 9.30am   | Suppiah V - Host genetics and treatment response in chronic hepatitis C interferon and ribavirin therapy  |
| 9.30am - 9.45am       | Wallace J - Health and security - Mixing oil and water? Regulating hepatitis C prevention in prisons                                     | 9.30am - 9.45am   | Deacon R - Correlates of hepatitis B vaccination status among injecting drug users: A comparison of eligible and ineligible participants in the havit trial                 | 9.30am - 9.45am   | Ferguson L - Providing an HCV service in a busy drug and alcohol service, without additional resources   | 9.30am - 9.45am   | D'Avigdor W - Correlation of miRNA and mRNA expression profiles differentiating hepatitis C (HCV) genotypes 1 and 3 liver injury                                |
| 9.45am - 10.00am      | Wilson H - Perception of hepatitis C risk among injecting drug users who obtain injecting equipment from pharmacies in Western Australia | 9.45am - 10.00am  | Newley N - Promotion and information with respect (pair) project  | 9.45am - 10.00am  | Tenison F - Onsite access to specialist hepatitis C medical clinics - Outcomes in outreach hepatitis C services in community based clinics                     | 9.45am - 10.00am  | Nachbur U - Hepatitis B virus inhibits ciap1 and increases sensitivity to TNF-alpha in primary hepatocytes  |
| 10.00am - 10.15am     | Newland J - Peer distribution: A pre-existing, effective and illegal model of sterile injection equipment distribution in NSW            | 10.00am - 10.15am | Gillman A - Assessment and treatment of chronic hepatitis C virus (HCV) infection in a prospective, observational cohort of injection drug users (IDUS): the ethos cohort   | 10.00am - 10.15am | Russell D - Equitable access to hepatitis C treatment: Establishing and maintaining an HCV clinic in a correctional facility                                   | 10.00am - 10.15am | Parsian H - Comparison of five liver fibrosis indexes with serum levels of laminin and n-terminal peptide of procollagen type III in chronic hepatitis patients |
| 10.15am - 10.30am     | Paquette D - Who doesn't get captured by a respondent-driven sampling survey of people who inject drugs?                                 | 10.15am - 10.30am | Douglas J - Development and evaluation of a nurse-led model of care for treatment of prisoners with chronic hepatitis C   | 10.15am - 10.30am | Baker D - Hepatitis C treatment initiation in primary care   | 10.15am - 10.30am | Discussion  |



|                   |   |                   |  |                   |   |                   |   |
|-------------------|---|-------------------|--|-------------------|---|-------------------|---|
| 10.30am - 11.00am | Morning Tea in Exhibition and Poster Area, Grand Foyer  |                   |  |                   |   |                   |   |
|                   | <b>Tackling Hepatitis C in Challenging Environments</b>   |                   | <b>Living with, Support and Treatment of Hepatitis C</b>   |                   | <b>Viral Hepatitis and HIV Co-Infection</b>   |                   | <b>Host Metabolism, Genetics and Viral Pathogenesis</b>   |
| 11.00am - 12.30pm | Grand 1 & 2<br><br>Chairs: Chris Cunningham & Sonam Paljor  | 11.00am - 12.30pm | Grand 3 & 4<br><br>Chairs: Nadia Gavin & Tracey Jones  | 11.00am - 12.30pm | Grand 6<br><br>Chairs: David Iser & Greg Dore   | 11.00am - 12.30pm | Grand 5<br><br>Chairs: Scott Friedman & Nick Shackel  |
| 11.00am - 11.20am | <b>Michael Levy, Director, Corrections Health Program, ACT, Australia</b><br><br>Human rights, prison and injecting drug use; Commissioning the health service in a human rights compliant prison.                    | 11.00am - 11.20am | <b>Max Hopwood, Research Fellow, National Centre in HIV Social Research, NSW, Australia</b><br><br>Support for people with hepatitis C: What is it, where do you get it and does it make any difference? | 11.00am - 11.20am | <b>Janaki Amin, National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, NSW, Australia</b><br><br>HIV and viral hepatitis coinfection: burden of disease  | 11.00am - 11.20am | <b>Amany Zekry, Senior Lecturer, St George Clinical School, Faculty of Medicine, UNSW, NSW, Australia</b><br><br>The effect of obesity on inflammatory response in hepatitis C                                  |
| 11.20am - 11.40am | <b>Stephen McNally, Senior Research Fellow, Australian Research Centre in Sex, Health and Society, La Trobe University, VIC, Australia</b><br><br>Recognising and responding to hepatitis C in Indigenous communities | 11.20am - 11.40am | <b>Suzanne Fraser, Centre for Women's Studies and Gender Research, School of Political and Social Inquiry, Monash University, VIC, Australia</b><br><br>Social constructions                             | 11.20am - 11.40am | <b>Gail Matthews, Senior Lecturer, Viral Hepatitis Clinical Research Program, National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, NSW, Australia</b><br><br>HIV/HCV co infection –transmission to treatment | 11.20am - 11.40am | <b>Silvana Gaudieri, Associate Professor, School of Anatomy &amp; Human Biology &amp; Centre for Forensics, University of Western Australia, WA, Australia</b><br><br>Host genetics and HCV disease progression |

|                   |   |                   |  |   |   |                   |  |
|-------------------|---|-------------------|--|---|---|-------------------|--|
| 11.40am - 12.00pm | <p><b>Fiona Poeder, Hepatitis C Program Manager, Australian Injecting and Illicit Drug Users' League, ACT, Australia</b></p> <p>Peers in mainstream organisations 'how can you be a 'peer' if you're not allowed to identify as a drug user?'</p>   | 11.40am - 12.00pm | <p><b>Robert Batey, Clinical Professor of Medicine, Sydney University, Senior Staff Specialist, Drug Health Services, RPAH Sydney, NSW, Australia</b></p> <p>Treating HCV in out of the way places; Who is doing what and do they need to?</p> | 11.40am - 12.00pm   | <p><b>Sharon Lewin, Director, Infectious Diseases Unit, Alfred Hospital; Professor of Medicine, Monash University; Co-head, Centre for Virology, Burnet Institute, Melbourne, VIC, Australia</b></p> <p>Pathogenesis of HIV-HBV co-infection: Implications for treatment strategies</p> | 11.40am - 12.00pm | <p><b>Elizabeth Powell, Associate Professor, University of Queensland and the Princess Alexandra Hospital, QLD, Australia</b></p> <p>Disease progression in HCV - Role of impaired hepatocyte replication, progenitor cells and host metabolic factors</p> |
| 12.00pm - 12.30pm | <p>Panel Discussion: Facilitator, Helen McNeill, CEO, Hepatitis Victoria, VIC, Australia<br/>Panellists:<br/>Michael Levy; Stephen McNally; Fiona Poeder;<br/>Jenny Kelsall, Team Leader, BBV Education &amp; Support, Harm Reduction Victoria;<br/>Sione Crawford, Community Programs Worker, NSW Users and AIDS Association<br/>Ross Morgan, Hepatitis Victoria</p> | 12.00pm - 12.30pm | Discussion   | 12.00pm - 12.20pm   | Discussion  | 12.00pm - 12.30pm | Discussion   |
|                   |   | 12.20pm - 12.30pm |  | Co-infection HIV & Viral Hepatitis: A guide for Clinical Management, Resource Launch, |   |                   |  |
| wford             | Lunch in Exhibition and Poster Area, Grand Foyer  |                   |  |   |   |                   |  |

|                 |   |
|-----------------|---|
| 1.30pm - 3.30pm | Closing Session: Moving Forward - Challenges for the Next Decade  |
| 1.30pm - 1.55pm | Grand 1 - 4<br>Chairs: Carla Treloar & John Hornell   |
| 1.30pm - 1.55pm | <b>Michael Kidd, Executive Dean of Health, Flinders University, South Australia and Chair of the Australian Government's Ministerial Advisory Committee on Blood Borne Viruses and Sexually Transmissible Infections, South Australia, Australia</b><br><br>Moving forward, policy into program |
| 1.55pm - 2.20pm | <b>Maria Prins, Senior Epidemiologist, Head Department of Research, Cluster Infectious Diseases, Health Service of Amsterdam, The Netherlands</b><br><br>Solving the key public health challenges in hepatitis C  |
| 2.20pm - 2.45pm | <b>Stephen Locarnini, Professor, Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, VIC, Australia</b><br><br>Drug resistance in hepatitis B has been defeated only to be replaced with hepatitis C  |
| 2.45pm - 3.10pm | <b>Chris Cunningham, Director, Research Centre for Māori Health &amp; Development, College of Humanities and Social Sciences, Massey University, New Zealand</b><br><br>Hepatitis B, policy into program  |
| 3.10pm - 3.20pm | Closing Remarks: Greg Dore, Representative of the 2010 Viral Hepatitis Conference Partners  |
| 3.20pm - 3.30pm | Presentation of the next conference: 8th Australasian Viral Hepatitis Conference 2012   |
| 3.30pm          | Conference Close  |